Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAST: Semaglutide in Acute Ischemic Stroke Post-EVT
NCT07511543Phase 2Not yet recruiting
- Sponsor
- Population Health Research Institute
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of semaglutide in ischemic stroke, sponsored by Population Health Research Institute. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07511543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511543.